Lumenis SLT Laser
Selective Laser Trabeculoplasty (SLT) was developed and brought to market by Lumenis
Today, Lumenis prides itself as the company with the most robust clinical data on SLT, the largest global installed-base of SLT products, the widest range of added-value products & services to maximize SLT potential in your practice – including robust patient education collateral & multimedia - and much more!
When you buy an SLT product from Lumenis, you gain immediate access to the largest network of SLT users worldwide, receive product upgrades & updates, advance-notice invitations to SLT symposia & workshops all around the world and a long list of other benefits which are exclusive to Lumenis SLT customers.
Furthermore, all Lumenis SLT products were designed to meet the clinically recommended SLT treatment protocol that we have helped to shape. Buying a Lumenis SLT product guarantees your ability to customize treatment on a case-by-case basis and meet SLT treatment protocol requirements.
The Clinical Advantages of Lumenis SLT
Selective Laser Trabeculoplasty (SLT) is a clinically proven laser treatment to reduce IOP without coagulating the Trabecular Meshwork. SLT represents an evolution over previous laser therapies as it can be safely repeated if needed.
Mechanism of Action:
Lumenis SLT technology uses a Q-switched, frequency-doubled Nd:YAG; 532 nm wavelength green laser. When applied to the target tissue, the laser is selectively absorbed by melanin-containing pigmented cells in the Trabecular Meshwork, without causing thermal or coagulative collateral damage to adjacent tissue. The increase in expression of biological cytokines and cellular mediator activities following laser irradiation recruit macrophages to the Trabecular Meshwork. In turn, macrophages remove obstructive proteins and remodel the Trabecular Meshwork, improving aqueous humor outflow and, thereby, reducing intraocular pressure (IOP).
For more information, visit www.glaucomaslt.com